Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients-Reference-Cited by-同舟云学术

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients

Published:2020-01 Issue: Volume:37 Page:101450
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Bianco Assunta^ORCID,Mari Pier-Valerio,Larici Anna Rita,Lucchini Matteo,Nociti Viviana^ORCID,Losavio Francesco Antonio^ORCID,De Fino Chiara^ORCID,Cicchetti Giuseppe^ORCID,Coraci Daniele,Richeldi Luca,Mirabella Massimiliano^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference12 articles.

1. Alemtuzumab and de novo pulmonary arterial hypertension: a potential association?;Beaumier;J. Heart Lung Transpl.,2017

2. Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts;Berger;CNS Drugs,2017

3. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis;Blasco;J. Neurol.,2017

4. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis;Buonomo;Mult.Scler.Relat. Disord.,2019

5. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations;Devonshire;J. Neurol,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab;Multiple Sclerosis and Related Disorders;2022-03

2. Natalizumab-induced pneumonitis;Journal of Neurology;2021-09-22

3. Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report;BMC Pediatrics;2021-05-12

4. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis;Vaccines;2020-12-26

5. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?;Expert Review of Neurotherapeutics;2020-10-10